Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Zevalin first-line monotherapy in untreated follicular non-Hodgkin lymphoma
2006-006808-11Phase 2Completed
- Sponsor
- IRCCS Ospedale Policlinico San Martino
- Start
- Jun 2007
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ibritumomab tiuxetan in follicular lymphoma (FL), sponsored by IRCCS Ospedale Policlinico San Martino. Primary endpoints: Efficacy and safety of single-dose Zevalin, Complete response rate and 2 more. Started Jun 2007; status: completed.
02
Drugs
ibritumomab tiuxetan
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on 2006-006808-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-006808-11.